CSL Limited Appoints Cameron Price as Non-executive Director

The latest announcement is out from CSL ( (AU:CSL) ).

CSL Limited has announced the appointment of Mr. Cameron Price as an independent Non-executive Director, effective October 1, 2025. Mr. Price brings extensive experience from his previous role as General Counsel & Chief Risk Officer at Australia’s Future Fund and his background in mergers & acquisitions and corporate governance. His appointment is expected to enhance CSL’s board with his insights and commercial acumen, potentially strengthening the company’s strategic positioning in global investment markets.

The most recent analyst rating on (AU:CSL) stock is a Buy with a A$310.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.

More about CSL

CSL Limited operates in the biotechnology industry, focusing on developing and delivering innovative medicines that save lives and improve the quality of life for people with rare and serious diseases. The company is known for its expertise in immunoglobulins, vaccines, and specialty products, and it serves a global market with a strong emphasis on research and development.

Average Trading Volume: 905,764

Technical Sentiment Signal: Sell

Current Market Cap: A$117.1B

Find detailed analytics on CSL stock on TipRanks’ Stock Analysis page.